Growth hormone could promote cancer, according to new research

Sep 21, 2007

Growth hormone and associated proteins could be responsible for promoting many types of cancer, including breast and prostate cancer, according to an Australian researcher.

Professor Mike Waters, from the Institute for Molecular Bioscience at The University of Queensland, said that blocking growth hormone action could be a useful avenue for cancer therapy.

He made the comments in a review published in the current issue of American scientific journal Endocrinology. His review found that many studies have reported a link between growth hormone and cancer, and a recent analysis found that people lacking growth hormone function are resistant to malignancies.

“There is also evidence that blocking growth hormone action can reduce both size and number of tumours,” Professor Waters said.

The review backed up Professor Waters' own research, published in August in the journal Proceedings of the National Academy of Sciences USA, which found growth hormone receptor could induce tumour growth when sent to the cell nucleus.

Growth hormone receptor is the protein that cells use to sense growth hormone, which determines the extent of growth after birth, and regulates metabolism.

Growth hormone receptor works from the surface of the cell, but can also be found in places within the cell, including the nucleus.

“Nuclear-localised growth hormone receptor has been reported in a number of cancers previously,” Professor Waters said. “But no one had analysed the consequences of this until our study.”

Professor Waters and his team found that nuclear localisation of growth hormone receptor is definitely associated with increased cell proliferation and spreading of malignant cells, leading to cancer.

“Cells need to multiply in order for us to grow, and it is growth hormone that triggers this proliferation,” Professor Waters said. “But if the cells multiply too quickly and aggressively, it can be dangerous for the body, and result in disorders such as cancer, so we have an in-built brake that stops the cells from proliferating too much.”

“When we sent growth hormone receptor into the nucleus of cells in mice, we found that this brake stopped working, the cells multiplied at a greater rate and tumours began to appear.”

Professor Waters said the ability of nuclear-localised growth hormone receptor to trigger tumour formation could have important clinical implications.

“Our findings indicate that nuclear growth hormone receptor could be targeted to treat proliferative disorders such as cancer, and strategies aimed at stopping growth hormone receptor from moving to the nucleus could result in useful cancer therapeutics. More generally, blocking growth hormone action in the adult should reduce the spread of cancer within the body without major side effects.”

Source: University of Queensland

Explore further: New drug target can break down cancer's barrier against treatment

add to favorites email to friend print save as pdf

Related Stories

Hoverbike drone project for air transport takes off

10 hours ago

What happens when you cross a helicopter with a motorbike? The crew at Malloy Aeronautics has been focused on a viable answer and has launched a crowdfunding campaign to support its Hoverbike project, "The ...

Study indicates large raptors in Africa used for bushmeat

11 hours ago

Bushmeat, the use of native animal species for food or commercial food sale, has been heavily documented to be a significant factor in the decline of many species of primates and other mammals. However, a new study indicates ...

Recommended for you

Study shows epigenetic changes can drive cancer

Jul 26, 2014

Cancer has long been thought to be primarily a genetic disease, but in recent decades scientists have come to believe that epigenetic changes – which don't change the DNA sequence but how it is 'read' – also play a role ...

User comments : 0